Long-term effects of HIV treatment in sub-Saharan Africa: from access to quality
Boender, T.S.

Citation for published version (APA):
Boender, T. S. (2016). Long-term effects of HIV treatment in sub-Saharan Africa: from access to quality

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
As HIV treatment programs in sub-Saharan Africa mature, there are rising concerns about the long-term sustainability and quality of these programs. Increasing levels of HIV drug resistance have been measured in sub-Saharan Africa, and could jeopardize long-term treatment success.

This thesis presents the results of prospective cohort studies in adults and children, assessing the quality of HIV treatment programmes and the emergence of HIV drug resistance in sub-Saharan Africa.
Long-term effects of HIV treatment in sub-Saharan Africa
from access to quality

Sonia Boender
Long-term effects of HIV treatment in sub-Saharan Africa: from access to quality.
Academic thesis, University of Amsterdam, the Netherlands.

Copyright ©2016, T. Sonia Boender, Amsterdam, the Netherlands. All rights reserved. No part of this publication may be reproduced, stored or transmitted in any forms or by any means, without written permission of the author.

ISBN: 978-94-6169-841-4

Cover & bookmark: Painting by Jjuuko Hoods 2014, Owino Kampala market road, oil and acrylics on canvas, 60x90cm, Kampala, Uganda [jjuukoods@gmail.com].
Layout & printing: Optima Grafische Communicatie, Rotterdam, the Netherlands.

The studies included in this thesis were initiated by PharmAccess Foundation, the Amsterdam Institute for Global Health and Development and the Department of Global Health at the Academic Medical Center of the University of Amsterdam, The Netherlands.
The PASER studies were funded by The Netherlands Ministry of Foreign Affairs in partnership with Stichting AidsFonds [grant 12454], de Grote Onderneming (Amsterdam Diner 2008), NWO-WOTRO under the Netherlands African Partnership for Capacity Development, Clinical Interventions against Poverty related Diseases [grant W.07.05.204.00], Heineken Africa Foundation, the Jura Foundation, the World Health Organization and the Embassy of the Kingdom of the Netherlands regional HIV/AIDS programme for Southern Africa.
The MARCH studies were funded by the European & Developing Countries Clinical Trials Partnership, NWO-WOTRO and Heineken Africa Foundation.
This PhD research was supported by the Global Child Health Group at the Emma Children’s Hospital/Academic Medical Center at the University of Amsterdam, The Netherlands.

The printing of this thesis was financially supported by the Academic Medical Center of the University of Amsterdam, Virology Education, AbbVie BV, Boehringer Ingelheim BV and Gilead Sciences Netherlands BV.
Long-term effects of HIV treatment in sub-Saharan Africa
from access to quality

ACADEMISCH PROEFSCHRIFT

ter verkrijging van de graad van doctor
aan de Universiteit van Amsterdam
op gezag van de Rector Magnificus
prof. dr. D.C. van den Boom
ten overstaan van een door het College voor Promoties ingestelde commissie,
in het openbaar te verdedigen in de Agnietenkapel
op vrijdag 20 mei 2016, te 12.00 uur

doort

Tamara Sonia Boender

geboren te Breda
Promotiecommissie

Promotores: Prof. dr. T.F. Rinke de Wit Universiteit van Amsterdam
Prof. dr. M. Boele van Hensbroek Universiteit van Amsterdam

Copromotores: Dr. K.C.E. Sigaloff Universiteit van Amsterdam
Dr. J.C.J. Calis Universiteit van Amsterdam

Overige leden: Prof. dr. R.A. Coutinho Universiteit Utrecht
Prof. dr. P. Reiss Universiteit van Amsterdam
Dr. D. Pajkrt Universiteit van Amsterdam
Prof. dr. F.G.J. Cobelens Universiteit van Amsterdam
Dr. A.M.J. Wensing Universitair Medisch Centrum Utrecht
Dr. A.S. Akanmu University of Lagos

Faculteit der Geneeskunde
# TABLE OF CONTENTS

Abbreviations 7

Chapter 1. General introduction 9

**Part I - Starting HIV treatment: pretreatment challenges**

Chapter 2. Barriers to initiation of pediatric HIV treatment in Uganda: a mixed-method study. 29
Chapter 3. HIV drug resistance among children initiating first-line antiretroviral treatment in Uganda. 51
Chapter 4. High levels of HIV drug resistance in treatment-naive children in Lagos, Nigeria: original data and a systematic review in sub-Saharan Africa. 71

**Part II - Long-term outcomes of first-line antiretroviral therapy**

Chapter 5. Virological suppression among HIV-infected children in low- and middle-income countries: a systematic review and meta-analysis. 91
Chapter 6. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis. 107
Chapter 7. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. 125

**Part III - Salvage drug options**

Chapter 8. Accumulation of HIV-1 drug resistance after continued virological failure on first-line antiretroviral therapy in adults and children in sub-Saharan Africa. 149
Chapter 9. Protease inhibitor resistance in the first three years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa. 171

**Epilogue**

Chapter 10. Research in action: from AIDS to global health to impact. A symposium in recognition of the scientific contributions of Professor Joep Lange. 197

Chapter 11. Summary & General discussion 215

**Addendum**

Nederlandse samenvatting (Summary in Dutch) 235
Authors & Affiliations 245
Acknowledgements / Dankwoord 253
PhD Portfolio 260
List of publications 262
Curriculum vitae 265
ABBREVIATIONS

3TC lamivudine
AZT azidothymidine (also referred to as ZDV)
ADR acquired drug resistance
AIDS acquired immunodeficiency syndrome
AIGHD Amsterdam Institute for Global Health and Development
ANC antenatal care
ART combination antiretroviral therapy
ARV antiretroviral (drug)
CRF circulating recombinant forms
DNA deoxyribonucleic acid
DRM drug resistance mutation
EDCTP European and Developing Countries Clinical Trials Partnership
EFV efavirenz
HAART highly active antiretroviral therapy
HIV human immunodeficiency virus
HIVDR HIV drug resistance
HR hazard ratio
IAS-USA International Antiviral Society-USA
ITT intention-to-treat
JCRC Joint Clinical Research Centre
LAASER Linking Asian and African Societies for an Enhanced Response to HIV/AIDS
LMIC low- and middle-income country
LUTH Lagos University Teaching Hospital
LTFU loss to follow-up
MARCH Monitoring Antiretroviral Resistance in Children
MTCT mother-to-child transmission
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
NVP nevirapine
OR odds ratio
OT on-treatment
PASER PanAfrican/PharmAccess Studies to Evaluate Resistance
PASER-M PASER-Monitoring
PCR polymerase chain reaction
PDR pretreatment drug resistance
PI protease inhibitor
PMTCT prevention of mother-to-child transmission
RNA ribonucleic acid
TAM thymidine analogue mutation
TASER TREAT Asia Asian Studies to Evaluate Resistance
VL HIV viral load
WHO World Health Organization
ZDV zidovudine (also referred to as AZT)